Lisata Therapeutics, Inc.
NCM: LSTALive Quote
📈 ZcoreAI Score
Our AI model analyzes Lisata Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get LSTA Z-Score →About Lisata Therapeutics, Inc.
Healthcare
Biotechnology
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
📊 Fundamental Analysis
Lisata Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -90.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -75.5%, which indicates that capital utilization is currently under pressure.
At a current price of $5.01, LSTA currently trades near the top of its 52-week range (98%) (Range: $1.81 - $5.07).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$45.25M
Trailing P/E
--
Forward P/E
-7.59
Beta (5Y)
1.11
52W High
$5.07
52W Low
$1.81
Avg Volume
174K
Day High
Day Low